Long-term quality-of-life outcomes following prostate radiotherapy with or without high-dose-rate brachytherapy boost: post-hoc analysis of TROG 03.04 RADAR

- Ong, Wee Loon, Nikitas, John, Nickols, Nicholas G., Chang, Albert, Zaorsky, Nicholas G., Spratt, Daniel E., Romero, Tahmineh, Kishan, Amar U., Joseph, David, Steigler, Allison, Millar, Jeremy, Valle, Luca, Steinberg, Michael L., Martin, Ting, Reiter, Robert E., Rettig, Matthew B.

Prostate-specific antigen response to androgen deprivation therapy in the neoadjuvant setting for high-risk prostate adenocarcinoma (PIRANHA): Pooled analysis of two randomized clinical trials

- Nikitas, John, Ong, Wee Loon, Carrier, Nathalie, Romero, Tahmineh, Millar, Jeremy, Steinberg, Michael L., Rettig, Matthew B., Boutros, Paul C., Reiter, Robert, Nickols, Nicholas G., Valle, Luca, McGuire, Sean E., Spratt, Daniel E., Souhami, Luis, Roy, Soumyajit, Martin, Jarad M., Joseph, David, Nabid, Abdenour, Kishan, Amar U.

A patient-centred approach to determine optimal supportive care across the cancer trajectory: a cross-sectional study

- Turon, Heidi, Hill, David, Watson, Rochelle, Hobden, Breanne, Millar, Jeremy, Sanson-Fisher, Rob

Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial

- Duchesne, Gillian M., Woo, Henry H., Millar, Jeremy, Milne, Roger, Smith, Rosemary G., Spry, Nigel, Stockler, Martin, Syme, Rodney A., Tai, Keen Hun, Turner, Sandra, Bassett, Julie K., Bowe, Steven J., D'Este, Catherine, Frydenberg, Mark, King, Madeleine, Ledwich, Leo, Loblaw, Andrew, Malone, Shawn